747-P: Baseline Characteristics of Subjects in the Once-Weekly (OW) Semaglutide FLOW Kidney Outcomes Trial
Richard E. Pratley(Translational Research Institute for Metabolism and Diabetes), VLADO PERKOVIC, George L. Bakris(Pennsylvania State System of Higher Education), KATHERINE R. TUTTLE, Henriette Mersebach, KENNETH W. MAHAFFEY, Peter Rossing(Steno Diabetes Centers), Jack Lawson, FLORIAN M.M. BAERES, JOHANNES F. MANN
Cited by 2
Related Papers
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
|Hypertension|2003|13.3k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2020|2.6k
A Controlled Trial of Renal Denervation for Resistant Hypertension
|New England Journal of Medicine|2014|2.2k